Key facts
- It has raised $4.4M across 2 recorded rounds; the latest was Seed Round ($3.7M) in Jan 2024.
- Notable investors include Caydan Capital Partners.
- MitoSense has filed 3 Form Ds with the SEC since 2023, most recently May 2025 ($3.7M sold to 16 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for MitoSense
Funding rounds
2 roundsAbout MitoSense
Operator of a medical research company intended to develop treatments for neurodegenerative diseases. The company utilizes mitochondrial organelle transplantation (MOT) technology to replenish the mitochondria in humans, enabling patients to overcome neurodegenerative diseases by harnessing the power of mitochondria.
- Sector
- Healthcare
- HQ
- Plymouth, MA, United States
- Founded
- 2019
- Website
- mitosenseinc.com/
- Ownership
- Privately Held (backing)
MitoSense doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MitoSense shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MitoSense in its N-PORT filings yet. We sweep new filings monthly.